Gynecologic Oncology | Specialty

The OncLive Gynecologic Oncology condition center page is a comprehensive resource for clinical news and expert insights on various types of gynecologic cancers, including ovarian cancer, endometrial cancer, and uterine cancer, among others. This section features news articles, interviews with gynecologic oncologists in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in gynecologic cancers.

Physicians Turn to Molecular Profiling to Drive Treatment Decisions in Endometrial Cancer

December 29th 2022

Ritu Salani, MD, MBA, discusses the continued evolution of molecular profiling in endometrial cancer, advances in immunotherapy for endometrial and cervical cancer, and ongoing research in gynecologic cancers.

Researchers Advance a Novel Screening Test for Early-Stage Ovarian and Endometrial Cancer

December 28th 2022

Peter Dottino, MD, FACOG, discusses the need for more accurate early screening tests for ovarian cancer, why testing for early-stage endometrial cancer is also important, the process used to develop the screening test, and how it could be implemented into practice if it is approved by the FDA.

Leading The Field of Rare Ovarian Cancers to New Heights

December 27th 2022

During his career, David M. Gershenson, MD, has helped turn ovarian cancer treatment into an evidence-based field and built better therapies through an improved biological understanding of the disease.

Approval of Mirvetuximab Soravtansine Provides Support for ADCs in the Ovarian Cancer Treatment Paradigm

December 26th 2022

Caroline Billingsley, MD, discusses the effect of mirvetuximab soravtansine’s approval on the treatment landscape in ovarian cancer and avenues for future research with antibody-drug conjugates and immunotherapy in this space.

Adverse Events Seen With Combination Lenvatinib and Pembrolizumab for Recurrent Endometrial Cancer

December 22nd 2022

Kimberly A. Spickes, CNP, details the adverse events she sees with combination lenvatinib and pembrolizumab treatment for recurrent endometrial cancer.

Monitoring Patients on Therapy for Recurrent Endometrial Cancer

December 22nd 2022

Kimberly Halla, NP, describes the standards for monitoring patients on therapy for recurrent endometrial cancer, including how often patients are seen in-person.

Overall Survival Is a Highly Relevant but Potentially Problematic End Point in Randomized Trials

December 21st 2022

Overall survival is a critically relevant end point in randomized oncology clinical trials, but its interpretation is often not as straightforward as some may wish to acknowledge.

Educating Patients With Endometrial Cancer on Treatment-Related Adverse Events

December 13th 2022

The panel explains how to educate patients on the adverse effects they may experience with chemotherapy, their options for management, and the importance of encouraging patients to contact their care team.

Treatment Options for Patients with Recurrent Endometrial Cancer

December 13th 2022

The panel reviews the second-line treatment options for patients with recurrent endometrial cancer.

Efficacy of Chemotherapy in Patients with Advanced Endometrial Cancer

December 7th 2022

Nurse Practitioner Kathleen Lutz talks about the efficacy of chemotherapy in patients with endometrial cancer, and how she discusses the chance of disease recurrence with patients.

Common Adverse Events Seen With Chemotherapy for Advanced Endometrial Cancer

December 7th 2022

Continuing her discussion, Kathleen highlights the most common adverse events she sees in patients treated with chemotherapy for advanced endometrial cancer who are unfit for surgery.

FDA Approvals of Immunotherapy in Gynecology Oncology

December 7th 2022

In this seventh episode of OncChats: Immunotherapy and You, John Nakayama, MD, and Ali Amjad, MD, walk through a timeline of FDA approvals of immunotherapy approaches in gynecologic oncology and discuss associated toxicities to be aware of as well as how to manage them.

FDA Approval Insights: Mirvetuximab Soravtansine in Platinum-Resistant Ovarian Cancer

December 5th 2022

Dr Matulonis discusses the FDA approval of mirvetuximab soravtansine-gynx in folate receptor alpha–positive, platinum-resistant ovarian cancer, key efficacy and safety data from the SORAYA trial, and how further research can continue the momentum behind finding effective ovarian cancer treatments.

Dostarlimab Plus Chemotherapy Combo Meets PFS End Point in Advanced or Recurrent Endometrial Cancer

December 2nd 2022

Dostarlimab plus standard-of-care chemotherapy, followed by dostarlimab alone, produced a statistically significant and clinically meaningful improvement in progression-free survival vs chemotherapy alone in patients with primary advanced or recurrent endometrial cancer.

Zimberelimab Monotherapy Elicits Responses in PD-L1–Positive Recurrent or Metastatic Cervical Cancer

December 1st 2022

Zimberelimab monotherapy demonstrated durable responses and was well tolerated in patients with PD-L1–positive, recurrent or metastatic cervical cancer who had progressed after first- or subsequent-line, platinum-containing chemotherapy, according to data from a phase 2 trial.

Nivolumab-Based Therapy Drives Durable Responses in Recurrent/Metastatic Cervical Cancer

November 30th 2022

Nivolumab alone or in combination with ipilimumab produced encouraging responses that were maintained over time in patients with recurrent or metastatic cervical cancer.

Immunotherapy and You: Checkpoint Inhibitors in Gynecologic Cancers

November 30th 2022

In this sixth episode of OncChats: Immunotherapy and You, John Nakayama, MD, and Ali Amjad, MD, highlight the success seen with checkpoint inhibitors in gynecologic cancers, biomarkers of interest, and recent approvals in the space.

First-Line Treatments for Patients With Advanced Endometrial Cancer Who Are Unfit for Surgery

November 29th 2022

Kathleen Lutz, RN, NP-BC WH, explains the most commonly used first-line treatment options in patients with advanced endometrial cancer who are unsuitable candidates for surgery.

Currently Available Treatment Modalities in Endometrial Cancer

November 29th 2022

The panel reviews the current treatment modalities for endometrial cancer and in what circumstances each is considered for a patient.

Extended Treatment Time With Bevacizumab Does Not Confer PFS Benefit in Ovarian Cancer

November 26th 2022

Increasing the duration of bevacizumab treatment in the frontline setting did not improve progression-free survival for patients with advanced ovarian cancer.